These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 8581665)

  • 21. [Leptin and fatty liver disease].
    Zhao CY; Li L
    Zhonghua Gan Zang Bing Za Zhi; 2004 Aug; 12(8):510-1. PubMed ID: 15329225
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of non-alcoholic fatty liver disease in children: swim at your own risk.
    Fischer R; Shneider B
    Pediatr Diabetes; 2009 Feb; 10(1):1-4. PubMed ID: 19161394
    [No Abstract]   [Full Text] [Related]  

  • 23. [Obesity and non-alcoholic steatohepatitis].
    Méndez-Sánchez N; Chávez-Tapia NC; Uribe M
    Gac Med Mex; 2004; 140 Suppl 2():S67-72. PubMed ID: 15641474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Non-alcohol steatohepatitis].
    Odintsova AKh; Kiiasov AP
    Eksp Klin Gastroenterol; 2005; (1):20-4. PubMed ID: 15991848
    [No Abstract]   [Full Text] [Related]  

  • 25. [Pathogenesis of non-alcoholic fatty liver and potential therapeutic targets].
    Crespo J; Cayón A; Pons-Romero F
    Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():15-23. PubMed ID: 15195530
    [No Abstract]   [Full Text] [Related]  

  • 26. [Advances in the epidemiological study of fatty liver].
    Zhang HJ; Zhuang H; Liu XE
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jul; 25(7):630-2. PubMed ID: 15308049
    [No Abstract]   [Full Text] [Related]  

  • 27. Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome.
    Boppidi H; Daram SR
    Postgrad Med; 2008 Jul; 120(2):E01-7. PubMed ID: 18654060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic and nutritional considerations in nonalcoholic fatty liver.
    Fong DG; Nehra V; Lindor KD; Buchman AL
    Hepatology; 2000 Jul; 32(1):3-10. PubMed ID: 10869282
    [No Abstract]   [Full Text] [Related]  

  • 29. Evaluation and management of obesity-related nonalcoholic fatty liver disease.
    Nugent C; Younossi ZM
    Nat Clin Pract Gastroenterol Hepatol; 2007 Aug; 4(8):432-41. PubMed ID: 17667992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pediatric nonalcoholic fatty liver disease in 2009.
    Alisi A; Manco M; Vania A; Nobili V
    J Pediatr; 2009 Oct; 155(4):469-74. PubMed ID: 19772998
    [No Abstract]   [Full Text] [Related]  

  • 31. Update on non-alcoholic fatty liver disease in children.
    Papandreou D; Rousso I; Mavromichalis I
    Clin Nutr; 2007 Aug; 26(4):409-15. PubMed ID: 17449148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [NASH now accepted as a diagnosis].
    Pikkarainen P
    Duodecim; 2003; 119(6):486-91. PubMed ID: 12708335
    [No Abstract]   [Full Text] [Related]  

  • 33. Surgical treatment for obesity and its impact on non-alcoholic steatohepatitis.
    Dixon JB
    Clin Liver Dis; 2007 Feb; 11(1):141-54, ix-x. PubMed ID: 17544976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic strategies in nonalcoholic fatty liver disorders.
    Poordad FF
    Expert Opin Emerg Drugs; 2005 May; 10(2):237-9. PubMed ID: 15934865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thin chance for fat people (to become living donors).
    Trotter JF
    Liver Transpl; 2001 May; 7(5):415-7. PubMed ID: 11349261
    [No Abstract]   [Full Text] [Related]  

  • 36. Steatosis: co-factor in other liver diseases.
    Powell EE; Jonsson JR; Clouston AD
    Hepatology; 2005 Jul; 42(1):5-13. PubMed ID: 15962320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Epidemiological survey of prevalence of fatty liver and its risk factors in a general adult population of Shanghai].
    Fang JG; Zhu J; Li XJ; Li R; Dai F; Song XM; Chen L; Li F; Chen SY
    Zhonghua Gan Zang Bing Za Zhi; 2005 Feb; 13(2):83-8. PubMed ID: 15727689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Obesity-induced lymphocyte hyperresponsiveness to chemokines: a new mechanism of Fatty liver inflammation in obese mice.
    Bigorgne AE; Bouchet-Delbos L; Naveau S; Dagher I; Prévot S; Durand-Gasselin I; Couderc J; Valet P; Emilie D; Perlemuter G
    Gastroenterology; 2008 May; 134(5):1459-69. PubMed ID: 18471520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obesity potentiates development of fatty liver and insulin resistance, but not atherosclerosis, in high-fat diet-fed agouti LDLR-deficient mice.
    Coenen KR; Hasty AH
    Am J Physiol Endocrinol Metab; 2007 Aug; 293(2):E492-9. PubMed ID: 17566116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition?
    Yang S; Lin HZ; Hwang J; Chacko VP; Diehl AM
    Cancer Res; 2001 Jul; 61(13):5016-23. PubMed ID: 11431335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.